Difference in Therapeutic Response Between Basal and Nonbasal Triple-Negative Breast Cancers
Abstract
This study, which nicely complements a study recently published in The Oncologist, shows for the first time that triple-negative breast cancers are much more heterogeneous than basal breast cancers regarding the response to chemotherapy and the probability of response to molecularly targeted therapies.